Christopher Coughlin - Allergan Plc Lead Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>AL</div>
AGN -- USA Stock  

Earning Report: 5th of May 2020  

Mr. Christopher J. Coughlin is Lead Independent Director of Allergan Plc. Mr. Coughlin joined the Board of Directors in July 2014 following the Companys acquisition of Forest Laboratories, Inc., having served as a member of the Board of Directors of Forest beginning 2011. Mr. Coughlin began serving as our Lead Independent Director in October 2016. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco until September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004, as Chief Financial Officer from August 2003 to June 2004 and as a director from July 2003 to July 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporationrationration from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996 he held various positions, including Chief Financial Officer, at Sterling Winthrop. In addition to the directorships listed below, Mr. Coughlin also previously served on the Board of Directors of Interpublic Group of Companies, Monsanto Company and Perrigo Company.
Age: 65  Director Since 2016      
862 261 7000  http://www.allergan.com
Coughlin has a B.S. in accounting from Boston College.

Christopher Coughlin Latest Insider Activity

Management Efficiency

The company has Return on Asset of (0.06) % which means that on every $100 spent on asset it lost $0.06. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.09) % meaning that it generated no profit with money invested by stockholders.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has Current Ratio of 0.98 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Ann CairnsAstrazeneca PLC
Craig ThompsonMerck Company
Jackson TaiEli Lilly And Company
Graham ChipchaseAstrazeneca PLC
Peter WendellMerck Company
Ton BuechnerNovartis AG
Robert BertoliniBristol Myers Squibb Company
Lewis CampbellBristol Myers Squibb Company
Patricia RussoMerck Company
Ian DavisJohnson Johnson
Jose BaselgaBristol Myers Squibb Company
Dinesh PaliwalBristol Myers Squibb Company
Wyllie CornwellPfizer
Susan LindquistJohnson Johnson
Inge ThulinMerck Company
John CoganGilead Sciences
Togo WestBristol Myers Squibb Company
Joseph EchevarriaPfizer
Alan LacyBristol Myers Squibb Company
Richard WhitleyGilead Sciences
Vindi BangaGlaxoSmithKline PLC

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on BATS Exchange in USA. It is located in Clonshaugh Business and Technology Park and employs 17,400 people. Allergan Plc is listed under Pharmaceutical Products category by Fama And French industry classification.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice PresidentView
Robert Bailey, Chief Legal Officer and Corporate SecretaryView
Robert Stewart, Executive VP and President of Generic and Global OperationsView
Ronald Taylor, Independent DirectorView
Adriane Brown, Independent DirectorView
William Meury, Executive Vice President, Chief Commercial OfficerView
Brenton Saunders, Chairman of the Board, President, Chief Executive OfficerView
Wayne Swanton, Executive Vice President - Global OperationsView
Robert Hugin, Independent DirectorView
Nicholson, Chief R&D OfficerView
Christopher Bodine, Independent DirectorView
Karen Ling, Chief Human Resource Officer, Executive Vice PresidentView
Michael Gallagher, Lead Independent DirectorView
Paul Bisaro, Executive ChairmanView
Thomas Freyman, Independent DirectorView
Catherine Klema, Lead Independent DirectorView
James DArecca, Chief Accounting OfficerView
Christopher Coughlin, Lead Independent DirectorView
Nesli Basgoz, Independent DirectorView
Philippe Schaison, Executive Vice President and President Allergan MedicalView
Maria Hilado, CFO and Executive VPView
Joseph Boccuzi, Independent DirectorView
Patrick OSullivan, Independent DirectorView
Fred Weiss, Independent DirectorView
A Bailey, Executive Vice President, Chief Legal Officer and Corporate SecretaryView
Alex Kelly, Chief Communications OfficerView
CDavid Nicholson, Executive Vice President, Chief R&D OfficerView
Carol Davidson, Independent DirectorView
Michael Greenberg, Independent DirectorView
Ron Taylor, Independent DirectorView
Jonathon Kellerman, Executive Vice President Chief Compliance OfficerView
Paul Navarre, Executive Vice President and President International BrandsView
James Bloem, Independent DirectorView
Karina Calzadilla, IR Contact OfficerView
Peter McDonnell, Independent DirectorView

Stock Performance Indicators

Current Sentiment - AGN

Allergan Plc Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Allergan Plc. What is your sentiment towards investing in Allergan Plc? Are you bullish or bearish?
98% Bullish
2% Bearish

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Eli Lilly And. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page